Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health and the National Cancer Institute are soliciting grant applications for the advanced development and validation of emerging technologies for basic and clinical cancer research. Supported projects must focus on enhancing, optimizing, and rigorously validating technologies where major feasibility gaps have already been overcome, in order to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate research in areas such as cancer biology, early detection, treatment, or epidemiology, while projects focusing solely on applying existing technologies to new biological questions are excluded. Applicants must provide supportive preliminary data demonstrating that the core technology is feasible and ready for advanced development. The National Cancer Institute expects to make approximately 14 awards with an award ceiling of $300,000 per grant, totaling an estimated program funding of $6,600,000, with applications closing on June 4, 2027.
Eligible Applicants
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Grant Documents
No documents available for this grant.